TrialJournal of pharmacokinetics and pharmacodynamics2026

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Yibo Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.